| Ye16) (2019) | 102 (51/51) | A : Catgut embeddingevery 15d,total 4 sessions | B : Acupuncture20-30min,3 times a week | (A) 60 days (B) 8 weeks | 1. Effective rate | 1. A>B(p<0.05) A : 49/51 B : 45/51 | NR |
| Chen17) (2019) | 120 (60/60) | A : Catgut embeddingevery 2w,total 6 sessions | B : Montelukast 10mgqd | 12 weeks | 1. TNSS① after 4 weeks② after 8 weeks③ after 12 weeks2. Effective rate | 1.① A<B(p<0.05) A : 4.24±2.58 B : 7.36±2.46② A<B(p0.05) A : 3.21±2.08 B : 5.58±2.10③ A<B(p<0.05) A : 2.56±2.44 B : 3.50±2.362. A>B(p<0.05) A : 55/60 B : 45/60 | NR |
| Zhang YM18) (2019) | 78 (39/39) | A : Catgut embeddingevery 10d,total 3 sessions | B : Loratadine 8.8mgqd | 1 month | 1. Symptom score① Itching② Rhinorrhea③ Nasal congestion④ Sneezing2. Effective rate3. Serum IgE level4. Recurrence rate① after 3 months② after 6 months | 1. A<B(p<0.05)① A : 0.76±0.14 B : 1.33±0.20② A : 0.75±0.14 B : 1.29±0.16③ A : 0.80±0.18 B : 1.35±0.21④ A : 0.62±0.12 B : 1.27±0.182. A>B(p<0.05) A : 37/39 B : 30/393. A<B(p<0.05) A : 108.56±10.23 B : 136.51±11.684. ① No significant difference between two groups A : 2/39 B : 6/39 ② A<B(p<0.05) A : 3/39 B : 10/39 | NR |
| Wei19) (2019) | 60 (30/30) | A : Catgut embeddingevery 2 w,total 2 sessions | B : Loratadine 10mgqd | 4 weeks | 1. Effective rate2. TNSS3. Serum IgE level4. Serum neuropeptide substance P level5. Recurrence rate after 1 year | 1.A>B(p<0.01) A : 27/30 B : 21/302. No significant difference between two groups A : 3.57±3.68 B : 2.97±4.653.A<B(p<0.05) A : 375.38±62.4 B : 423.06±81.534.A<B(p<0.01) A : 1.047±0.897 B : 2.450±0.7615.A<B(p<0.05) A : 4/31 B : 13/34 | NR |
| Cai20) (2018) | 80 (40/40) | A : Catgut embeddingevery week,total 4 sessions | B : Levocetirizine 5mgqd | 4 weeks | 1.Effective rate | 1. A>B(p<0.05) A : 38/40 B : 31/40 | A: Epistaxis(1)B: Epistaxis(2), Sore throat(3), Tingling in nasal mucosa(3), |
| Tan21) (2018) | 90(45/45) | A : Catgut embeddingevery 10 d,total 6 sessions | B : Cetirizine 5mgbid | 2 months | 1. Effective rate① after treatment② after 6 month2. RQLQ① after treatment② after 6 month3. Serum IgE level after treatment | 1. ① A<B(p<0.05) A : 25/40 B : 34/39 ② A>B(p<0.01) A : 37/40 B : 23/391. ① No significant difference between two groups ② A<B(p<0.05) especially in Sleep, Emotion, Nasal symptom category; Sleep A : 3.12±2.28 B : 4.89±4.12 Emotion A : 3.86±3.25 B : 4.69±3.76 Nasal symptom A : 5.93±4.32 B : 6.78±5.692. No significant difference between two groups A : 186.41±46.58 B : 182.66±44.86 | A : Fatigue & mild fever (3), Slight redness and swelling on ST36(2), Bruise and lump on CV4(3)B : Dizziness, Drowsiness, Nausea, Vomitting(7) |
| Zhang FB22) (2017) | 60(30/30) | A : Catgut embedding2 times a week,totla 8 sessions | B : Nasonex(mometasone furoate nasal spray)2 times on each side, qd | 4 weeks | 1. Effective rate after treatment2. Recurrence rate after 2 months | 1. No significant difference between two groups A : 28/30 B : 28/302. No significant difference between two groups A : 11/30 B : 5/30 | NR |
| Li GW23) (2017) | 76(38/38) | A : Catgut embeddingevery 20 d,total 9 sessions | B : Acupuncture30 min, qd (treatment 10 days and then rest 3 days) | 6 months | 1. Effective rate | 1. A>B(p<0.05) A : 36/38 B : 30/38 | NR |
| Li XR24)(2016) | 128(64/64) | A : Catgut embeddingevery 2 w,total 2 sessions | B : Sham catgutevery 2 w, total 2 sessions | 2 weeks | 1. VAS① at week 2② at week 102. RQLQ① at week 4② at week 10 | 1. ① No significant difference between two groups ② No significant difference between two groups2. ① A<B(p<0.05) A : 78.67±8.57 B : 84.471±6.883> ② A<B(p<0.05) A : 73.73±10.48 B : 79.807±6.221 | A : Subcutaneous induration on LI20 or EX-HN3(3), Ache on ST36(1)B : Ache on ST36(3) |
| Xu25) (2014) | 80(40/40) | A : Catgut embeddingevery 15 d,total 4 sessions | B : Loratadine 10mgqd (treatment 28 days and then rest 4 days) | 60 days | 1. Effective rate2. IL-4 level3. IFN-γ level | 1. A>B(p<0.01) A : 36/40 B : 28/402. A<B(p<0.05) A : 10.3±3.5 B : 12.4±4.3A>B(p<0.05) A : 57.2±4.3 B : 52.5±3.0 | NR |
| Meng26) (2013) | 80(40/40) | A : Catgut embeddingevery 15 d,total 4 sessions | B : Loratadine 10mgqd (treatment 28 days and then rest 4 days) | 60 days | 1. Effective rate① after treatment② after 1 month③ after 3 months④ after 6 months | 1. ① A>B(p<0.01) A : 36/40 B : 28/40 ② A>B(p<0.01) A: 34/40 B : 27/40 ③ A>B(p<0.01) A : 32/40 B : 26/40 ④ A>B(p<0.01) A : 30/40 B : 24/40 | NR |